Description of fracture with endocrine therapy use in older breast cancer survivors in a population-based setting Taryn Becker 123, Geoff Anderson 123,

Slides:



Advertisements
Similar presentations
Breast cancer chemoprevention in the high-risk patient
Advertisements

Obesity at Diagnosis Is Associated with Inferior Outcomes in Hormone Receptor Positive Breast Cancer 1 The Impact of Body Mass Index (BMI) on the Efficacy.
ATLAS Steering Committee: 24 September 2005 Steering Committee meeting, 24 th September 2005 University of Oxford Examination Schools.
Purposes and uses of cancer registration E.E.U. Akang Department of Pathology University College Hospital Ibadan, Nigeria.
Giving Induction Radiation in Addition to Chemotherapy Is Not Associated with Improved Survival of NSCLC Patients with Operable Mediastinal Nodal Disease.
Clinical Relevance of HER2 Overexpression/Amplification in Patients with Small Tumor Size and Node-Negative Breast Cancer Curigliano G et al. J Clin Oncol.
Impact of Cancer Diagnosis and Chemotherapy on Mammography Use Xinhua Yu, M.B., Ph.D. A. Marshall McBean, M.D., M.Sc. Beth A. Virnig, Ph.D., M.P.H Division.
Meta-analysis of trials of radiotherapy in DCIS Early Breast Cancer Trialists’ Collaborative Group (EBCTCG)
As noted by Gary H. Lyman (JCO, 2012) “CER is an important framework for systematically identifying and summarizing the totality of evidence on the effectiveness,
NON-STEROIDAL ANTI-INFLAMMATORY DRUGS AND PANCREATIC CANCER RISK: A NESTED CASE-CONTROL STUDY Marie Bradley, Carmel Hughes, Marie Cantwell and Liam Murray.
Study Of Letrozole Extension
The influence of Breast Cancer Pay for Performance Initiatives on breast cancer survival and performance measures: a pilot study in Taiwan Raymond NC Kuo,
The Effect of Zoledronic Acid (ZOL) on Aromatase Inhibitor-Associated Bone Loss in Postmenopausal Women with Early Breast Cancer Receiving Adjuvant Letrozole:
Long-Term Effects of Continuing Adjuvant Tamoxifen to 10 Years versus Stopping at 5 Years After Diagnosis of Oestrogen Receptor- Positive Breast Cancer:
1 Leveraging the Culture of Performance Excellence in Ontario’s Health System HSPRN is an inter-organization Network funded by the Ontario Ministry of.
1 Journal Club Alcohol, Other Drugs, and Health: Current Evidence January–February 2014.
Outcomes of screening mammography among women aged 40 to 43 Institute for Clinical Evaluative Sciences Toronto, Canada (2006)
Oral Bisphosphonate and Breast Cancer: Prospective Results from the Women’s Health Initiative (WHI) Chlebowski RT et al. SABCS 2009; Abstract 21.
Skull Base Chordoma and Chondrosarcoma: Changes in National Radiotherapy Patterns and Survival Outcomes Henry S. Park, MD, MPH; Kenneth B. Roberts, MD;
Clinical Trial Results. org Relationship Between Adherence to Evidence- Based Pharmacotherapy and Long-term Mortality After Acute Myocardial Infarction.
A role for lipids and statins in breast cancer risk and prevention? Dr. Mieke Van Hemelrijck Senior Lecturer in Cancer Epidemiology 3 August 2015.
Background  Reports of long-term survivors (≥5 years) of locally advanced esophageal cancer (LAEC) have focused mainly on HRQL or GI symptoms  Only.
ORIGIN Outcome Reduction with an Initial Glargine Intervention (ORIGIN) Trial Overview Large international randomized controlled trial in patients with.
BIG 1-98/IBCSG Henning Mouridsen for the BIG 1-98 Collaborative Group Authors: Sunil Verma Date posted: December 22, 2008.
Real-World Assessment of Clinical Outcomes in Lower-Risk Myelofibrosis Patients Receiving Treatment with Ruxolitinib Davis KL et al. Proc ASH 2014;Abstract.
Best first ? The ATAC completed treatment analysis Professor Jack Cuzick Wolfson Institute of Preventive Medicine, London, UK.
The Use of Trastuzumab in the Elderly in the Adjuvant Setting and After Disease Progression in Patients with HER2-Positive Advanced Breast Cancer Dall.
San Antonio Breast Cancer Symposium 2012 Helen K. Chew, MD, FACP Professor of Medicine.
1Bachelot T et al. Proc SABCS 2010;Abstract S1-6.
Published online July 24, Aromatase inhibitors versus tamoxifen in early breast.
Aubert RE et al. ASCO 2009; Abstract CRA508. (Oral Presentation)
Breast Cancer in the Women’s Health Initiative Trial of Estrogen Plus Progestin For the WHI Investigators Rowan T Chlebowski, MD., Ph.D.
Acknowledgements This report differs from the submitted abstract due to further subdivision of patients into analytic and non- analytic, and focus on the.
Evidence for a Survival Benefit Conferred by Adjuvant Radiotherapy in a Cohort of 608 Women with Early-stage Endometrial Cancer O. Kenneth Macdonald 1,
The Role of Residential Segregation in Disparity Research: A Case Example of ADHD Diagnosis and Treatment Dinci Pennap, MPH, 1 Mehmet Burcu, MS, 1 Daniel.
FREEDOM FROM PROGRESSION FOR PATIENTS RECEIVING I 125 VERSUS Pd 103 FOR PROSTATE BRACHYTHERAPY Jane Cho, Carol Morgenstern, Barbara Napolitano, Lee Richstone,
Anastrozole (‘Arimidex’): a new standard of care?
‘Arimidex’, Tamoxifen, Alone or in Combination (ATAC) trial: Completed Treatment Analysis.
Long-term mortality and thrombolysis therapy after a first acute ischemic stroke: gender differences. Ebrictus II Study. Authors & Affiliations Clua-Espuny.
ESMO 2011 Breast Cancer BOLERO-2 Authors: CARE Faculty (Drs. Anil Joy and Sunil Verma) Date posted: October 12, 2011.
S1207: Phase III Randomized, Placebo-Controlled Clinical Trial Evaluating the Use of Adjuvant Endocrine Therapy +/- One Year of Everolimus in Patients.
Kathleen Decker Alain Demers Daniel Chateau Marion Harrison Cervical Cancer in Manitoba: evaluating risk, Pap test utilization, and access CancerCare Manitoba.
Joanne Edwards Medical Information Manager ASCO Tech Assessment Update Commercial Implications & Promotional Guidance.
HERA TRIAL: 2 Years versus 1 Year of Trastuzumab After Adjuvant Chemotherapy in Women with HER2-Positive Early Breast Cancer at 8 Years of Median Follow-Up.
BC Cancer Agency CARE & RESEARCH Breast Cancer Mortality After Screening Mammography in British Columbia Women Andrew J. Coldman, Ph.D. Norm Phillips,
Re-fracture risk in older patients prescribed bisphosphonates Chiara Sorge Rome, 15th October 2012.
Treatment Options for Postmenopausal Women With Early-Stage Hormone Receptor–Positive Breast Cancer Recent Trials and Future Directions Harold Burstein,
2 years versus 1 year of adjuvant trastuzumab for HER2-positive breast cancer (HERA): an open-label, randomised controlled trial Aron Goldhirsch, Richard.
Adjuvant Chemotherapy for Non–Small-Cell Lung Cancer in the Elderly: A Population-Based Study in Ontario, Canada JOURNAL OF CLINICAL ONCOLOGY, VOLUME 30.
Sex-specific trends in lung cancer incidence and survival : a population study of cases 호흡기 내과 R3 조주희 Thorax 2011;66: Camilla M T Sagerup,
Post-It Notes to Improve Questionnaire Response Rates in RCTs Findings from a Randomised Sub-Study Ada Keding 1, Helen Lewis 2, Kate Bosanquet 2, Simon.
Date of download: 6/23/2016 From: Relative Effectiveness of Osteoporosis Drugs for Preventing Nonvertebral Fracture Ann Intern Med. 2008;148(9):
Date of download: 6/24/2016 Copyright © The American College of Cardiology. All rights reserved. From: The Year in Cardiovascular Surgery J Am Coll Cardiol.
ABSTRACT Purpose This retrospective review was conducted to determine if delay in the start of radiotherapy after conservative breast surgery had any detrimental.
Patterns of care and comparative effectiveness of endocrine therapy for premenopausal women with early breast cancer A multi-institution cohort study February.
Consequences Of Non-Compliance To Osteoporosis Medication Among Osteoporotic Women Ankita Modi, Ph.D, M.D. 1, Jackson Tang, M.Sc. 2, Shuvayu Sen, Ph.D.
J Clin Oncol 30: R2 윤경한 / Prof. 김시영 Huan Jin, Dongsheng Tu, Naiqing Zhao, Lois E. Shepherd, and Paul E. Goss.
MA.17R: Reduced Risk of Recurrence With Extending Adjuvant Letrozole Beyond 5 Yrs in Postmenopausal Women With Early-Stage Breast Cancer CCO Independent.
JAMA Internal Medicine May 2015 Volume 175, Number5 R1 조한샘 / Prof. 이창균.
Association Between Serotonergic Antidepressant Use During Pregnancy and Autism Spectrum Disorder in Children Hilary K. Brown, PhD; Joel G. Ray, MD, MSc,
JOURNAL OF CLINICAL ONCOLOGY 25:
Presenter: Wen-Ching Lan Date: 2018/08/01
Benefits of switching postmenopausal women with hormone-sensitive early breast cancer to anastrozole after 2 years adjuvant tamoxifen: Combined results.
Annals of Internal Medicine • Vol. 167 No. 12 • 19 December 2017
The Research Question RESEARCH METHOD
Effect of Obesity on Prognosis after Early Breast Cancer
Physical Activity and Endometrial Cancer Survival
Into the weeds: Understanding scientific articles
Assessment of Breast and Colorectal Cancer Surgery in Manitoba
Presentation transcript:

Description of fracture with endocrine therapy use in older breast cancer survivors in a population-based setting Taryn Becker 123, Geoff Anderson 123, Thiwanka Wijeratne 123, Lorraine Lipscombe 123, Andrea Gruneir 123, Ophira Ginsburg 123, Amy Finch 13, Paula Rochon Women’s College Research Institute 2. Institute for Clinical Evaluative Sciences 3. University of Toronto MethodsPreliminary Results Work in Progress Acknowledgements It is standard practice to treat postmenopausal women with localized hormone-receptor positive breast cancer with adjuvant hormone therapy (HT) While tamoxifen had been the mainstay of therapy, there is increasing evidence to support aromatase inhibitor (AI) use as the preferred treatment The 5 year survival among early breast cancer patients is greater than 87% Increased survival underscores the importance of monitoring for, preventing and treating long term unintended outcomes of HT AIs are associated with a higher fracture rate compared to tamoxifen. Clinical trials with over 100 months of follow-up, suggest that the fracture risk is not significant after treatment is completed However, current evidence is limited: Highly restricted patient population, which may not be representative of the “real world” There is an under-representation of older women with increased baseline fracture risk Study design Retrospective population-based cohort design, using administrative databases in Ontario Study population Women aged 66 years and older Women in Ontario diagnosed with invasive breast cancer Diagnosed between April 1, 1996 and March 31, 2006 Underwent breast cancer surgery within 1 year of diagnosis Were alive at 365 days from diagnosis Commenced taking hormone therapy within 1 year of diagnosis Exposure There were two exposure categories: AI or Tamoxifen started within 1 year of diagnosis Exposure was based on drug claims from the Ontario Drug Benefit database: First prescription within 1 year of diagnosis Second prescription within 150% of days of the first prescription Outcomes Primary: Fracture Emergency Room (ER) visit or hospitalization for fracture Spine, hip, lower extremity, upper extremity, wrist/forearm Excludes: in context of trauma or pathologic fracture Follow-up Begins 365 days after cancer diagnosis There is at least a 3-year follow-up allowed for each woman in the cohort Patients will be followed from diagnosis until the first occurrence of Fracture Death Cancer recurrence or new malignancy End of follow-up window (March 31, 2009). Ongoing Analysis Descriptive statistics among users of tamoxifen and AI Patient characteristics, health care usage patterns, pre-existing risk factors for fall and fracture Relationship between hormonal therapy and fracture Cox proportional hazards regression analysis Stratified analyses by previous fracture or osteoporosis Special Considerations Competing risks analysis (death, cancer recurrence) To examine the fracture risk in users of hormone therapy To examine the fracture risk with HT, stratifying by pre-treatment osteoporosis or previous fracture Look-back Window (up to 5 years) Observation Window (April March 2009) Breast cancer diagnosis Accrual Window (April 1996-March 2006) Maximum Follow-up Date (March 2009) Time Study-specific Dates 1 year We would like to thank Lingsong Yun, Sunila Kalkar, Wei Wu and Peter Anderson for their technical assistance. This study was conducted with the support of funding provided by the Ontario Institute for Cancer Research and Cancer Care Ontario (through funding provided by the Ministries of Health and Research & Innovation of the Government of Ontario). This study is also supported by the Institute for Clinical Evaluative Sciences (ICES), which is funded by an annual grant from the Ontario Ministry of Health and Long-Term Care (MOHLTC). The opinions and conclusions reported in this paper are those of the authors and are independent from the funding sources. No endorsement by ICES or the Ontario MOHLTC is intended or should be inferred. Background Objectives Implications These data indicate that fractures are common in this population It is important to further examine which women are at higher risk for fracture, while taking HT as adjuvant therapy for breast cancer. This will help: Facilitate informed therapy selection Guide targeted prevention, monitoring, early intervention 9348 women were identified in the cohort Overall rates of fracture in the entire cohort were 5.8% for hip fractures and 2.8% for spine fractures 7992 (85%) prescribed Tamoxifen and 1356 (15%) were prescribed AI The mean (SD) age was 74.8 (6.3) years Treatment duration yr (SD): 3.03 (1.55) Median Follow up yr (IQR).: 4.13 ( ) Hip Spine Fracture Rate (%)